Inflammation and anaemia as predictors of cardiovascular mortality in hemodialysis patients

Hippokratia

Volumn 11, Issue 1, 2007, Pages 39-43

  Selim, G ^a   Stojceva Taneva, O ^a   Ivanovski, N ^a   Zafirovska, K ^a   Sikole, A ^a   Trajcevska, L ^a   Asani, A ^a   Polenakovic, M ^b  

^a SS CYRIL AND METHODIUS UNIVERSITY   (Macedonia)

^b MACEDONIAN ACADEMY OF SCIENCES AND ARTS   (Macedonia)

Author keywords

Cardiovascular mortality; CRP; Hemodyalisis; Non traditional cardiovascular risk factor

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; CALCIUM; FIBRINOGEN; HEMOGLOBIN;

ADULT; AGED; ANEMIA; ARTICLE; CALCIUM BLOOD LEVEL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; INFECTION; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PROTEIN BLOOD LEVEL; SEPSIS;

EID: 33847710233     PISSN: 11084189     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. US Renal Data System. 2002 Annual Data Report. The National Institutes of Health , National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD; 2002
2. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32: S112-119
3. Cheung AK, Sarnak MJ, Yan G, et al. Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int 2000;58: 353-362
4. Zoccali C. Cardiovascular risk in uraemic patients-is it fully explained by classical risk factors? Nephrol Dial Transplant 2000;15: 454-457
5. K/DOQI Clinical Practice Guidelines for Cardiovascular Disease in Dialysis Patients, 2002
6. Foley RN, Parfrey PS, Harnett JD, et al. The impact of Anaemia on cardiomyopathy, morbidity and mortality in end-stage renal disease. Am J Kidney Dis 1996; 28: 53-61
7. Strippoli GF, Craig JC, Manno C, Schena FP. Hemoglobin Targets for the Anaemia of Chronic Kidney Disease: A Meta-analysis of Randomized, Controlled Trials. J Am Soc Nephrol 2004; 15: 3154-1365
8. Besarab A, Bolton WK, Browne JK, et al: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Eng J Med 1998; 339: 584-590
9. Locatelli F, Pisoni RL, Combe C, et al: Anaemia in five European countries and associated morbidity and mortality among haemodialysis patients:results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2004;19:121-132
10. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phoshorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31:607-617
11. Slinin Y, Foley RN, Collins AJ. Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDA waves 1, 3, and 4 study. J Am Soc Nephrol 2005; 16: 1788-1793
12. Young EW, Albert JM, Satayathum S, et al. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2005; 67: 1179-1187
13. Eknoyan G, Beck GJ, Cheung AK, et al. Effect of dialysis dose and membrane flux on mortality and morbidity in maintenance hemodialysis patients. N Eng J Med 2002; 347: 2010-2019
14. Pifer TB, McCullough KP, Port FK, et al. Mortality risk in hemodialysis patients and changes in nutritional indicators: DOPPS. Kidney Int 2002; 62: 2238-2245
15. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. Hypoalbuminemia, cardiac morbidity, and mortality in end-stage renal disease. J Am Soc Nephrol 1996; 7: 728-736
16. Zimmermann J, Herrlinger S, Pruy A, et al. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999; 55: 648-658
17. Yeun JY, Levi RA, Anadilok VM, Kaysen GA. C-Reactive Protein predicts al-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 2002; 35: 469-476
18. Wanner Ch, Metzger Th. C-reactive protein a marker for all-cause and cardiovascular mortality in hemodialysis patients. Nephrol Dial Transplant 2002; S 17: 29-32
19. Tripepi G, Mallamci F, Zoccali C. Inflammation markers, adhesion molecules, and all-cause and cardiovascular mortality in patients with ESRD: Searching for the best risk marker by multivariate modelling. J Am Soc Nephrol 2005; 16:S83-S88
20. Giocoechea M, Martin J, de Sequera P, et al: Role of cytokines in the response to erythropoietin in hemodialysis patients. Kidney Int 1998; 54: 1337-1343